WBSCR19 Inhibitors
WBSCR19 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the WBSCR19 protein. The acronym WBSCR19 stands for Williams-Beuren Syndrome Chromosomal Region 19, indicating that the gene encoding this protein is located within a region that is commonly deleted in individuals with Williams-Beuren Syndrome, a complex developmental disorder. The WBSCR19 protein itself is involved in multiple cellular processes, although its precise biological functions are not fully elucidated. Inhibitors of this protein may alter various molecular pathways by interfering with its normal activity. The chemical structure and properties of WBSCR19 inhibitors can vary widely, but they share the common feature of being able to bind to the WBSCR19 protein in some capacity, affecting its interaction with other cellular components.
The development and study of WBSCR19 inhibitors involve sophisticated chemical and biological techniques to ensure specificity and efficacy. Researchers often utilize high-throughput screening methods to identify potential inhibitors from large libraries of compounds, followed by iterative cycles of optimization through medicinal chemistry. Binding assays, X-ray crystallography, and computational modeling are commonly employed to explore the interaction between the inhibitors and the WBSCR19 protein at the molecular level. These studies help to refine the inhibitors' chemical structures to improve their ability to interact with the protein's active site or allosteric sites. As with any class of protein inhibitors, the stability, solubility, and selectivity of WBSCR19 inhibitors are critical parameters that are rigorously assessed during the development process to ensure that these molecules can effectively reach their target within the complex cellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ML-792 | 1644342-14-2 | sc-507423 | 10 mg | $390.00 | ||
ML-792 is a SUMOylation inhibitor that targets the SUMO activating enzyme, thereby preventing the SUMO modification of proteins. Since SUMOylation can impact the stability and function of a variety of proteins, inhibiting this process can indirectly affect the function of WBSCR19 by disrupting its post-translational modification. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting this pathway, the phosphorylation and activation of downstream effectors are reduced, which can lead to a decrease in the functional activity of WBSCR19 if it is involved in this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT signaling pathway. Given that the PI3K/AKT pathway is involved in many cellular processes, including protein synthesis and degradation, LY294002 could indirectly lead to a decrease in WBSCR19 activity by altering this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may impede the response to stress signals that could affect WBSCR19 indirectly by modifying the cellular stress response mechanisms in which WBSCR19 might participate. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are critical enzymes in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can suppress the activation of ERK, potentially affecting the functional activity of WBSCR19 if it is regulated by this pathway. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 free base | sc-202651 | 5 mg | $148.00 | 4 | |
BIX-01294 is a G9a histone methyltransferase inhibitor, which can lead to changes in chromatin structure and gene expression. As such, this could indirectly decrease the functional activity of WBSCR19 by altering the transcriptional regulation of genes that WBSCR19 may control. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can modulate the activity of transcription factors and other proteins. Inhibition of JNK signaling could diminish WBSCR19's role in gene regulation if it is involved in the JNK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which affects protein synthesis and cell growth by inhibiting the mTORC1 complex. This could lead to an indirect decrease in WBSCR19 activity by altering the protein's synthesis or degradation processes. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. By blocking EGFR signaling, it could indirectly impact WBSCR19's function if WBSCR19 is involved in pathways downstream of EGFR. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Chetomin disrupts the interaction between hypoxia-inducible factor (HIF) 1α and the transcriptional coactivator p300/CBP. As WBSCR19 may be involved in hypoxia-responsive gene regulation, chetomin could indirectly reduce WBSCR19 activity by affecting these pathways. | ||||||